An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM).

Schmidt, Stephan; Koehler, Jürgen; Winterstein, Christine; Schicklmaier, Petra; Kallmann, Boris

Schmidt, Stephan; Koehler, Jürgen; Winterstein, Christine; Schicklmaier, Petra; Kallmann, Boris.

Afiliación

Schmidt S; Neurologische Gemeinschaftspraxis, Kölnstr. 54, 53111 Bonn, Germany.
Koehler J; Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke Gemeinnützige GmbH, Kempfenhausen, Germany.
Winterstein C; Biogen, Medical Department, Munich, Germany.
Schicklmaier P; Biogen, Medical Department, Munich, Germany.
Kallmann B; Multiple Sklerose Zentrum Bamberg (MSZB), Bamberg, Germany.

Ther Adv Neurol Disord ; 11: 1756285617749802, 2018.

Article en En | MEDLINE | ID: mdl-29399053

Palabras clave

Disease-modifying therapies; Multiple Sclerosis; NEDA; treatment optimization

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Idioma: En Revista: Ther Adv Neurol Disord Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google